Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites

Bibliography

• Zeidler R, Reisbach G, Wollenberg B, Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, Csanady M, The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br J Cancer 2000;83:261-6
   PubMed Web of Science ®Google Scholar
• Riesenberg R, Buchner A, Pohla H, Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alphaEpCAM × alphaCD3). J Histochem Cytochem 2001;49:1-7
   PubMed Web of Science ®Google Scholar
• Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by trifunctional antibodies. Blood 2001;8:2526-34
   Web of Science ®Google Scholar
• Schmitt M, Schmitt A, Reinhardt P, Opsonization with a trifunctional bispecific (alphaCD3 × alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004;25:841-8
   PubMed Web of Science ®Google Scholar
• Ruf P, Gires O, Jager M, Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97:315-21
   PubMed Web of Science ®Google Scholar
• Ayhan A, Gultekin M, Taskiran C, Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 2007;17:68-75
   PubMed Web of Science ®Google Scholar
• Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007;18:945-9
   PubMed Web of Science ®Google Scholar
• Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006;42:589-97
   PubMed Web of Science ®Google Scholar
• Thomsen TW, Shaffer RW, White B, Setnik GS. Paracentesis, Videos in clinical medicine. N Engl J Med 2006;355(19):e21
   PubMed Web of Science ®Google Scholar
• Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 2007;47:1104-18
   PubMed Web of Science ®Google Scholar
• Gronau SS, Schmitt M, Thess B, Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 2005;27:376-82
   Google Scholar
• Walz A, Mack B, Schmitt B, Antitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids. Anticancer Res 2004;4:887-93
   Google Scholar
• Morecki S, Lindhofer H, Yacovlev E, Use of trifunctional bispesific antibodies to prevent graft versus host disease induced by allogenic lymphocytes. Blood 2006;107:1564-9
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010: Published online 27 April 2010: doi:10.1002/ijc.25423
   PubMed Web of Science ®Google Scholar
• Burges A, Wimberger P, Kumper C, Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a Phase I/II study. Clin Cancer Res 2007;13:899-905
   Web of Science ®Google Scholar
• Ruf P, Kluge M, Jager M, Pharmacokinetics, immunogenicity, and bioactivity of the therapeutic antibody catumaxoamb intraperitoneally administered to cancer patients. Br J Clin Pharmacol 2010;69:617-25
   Google Scholar
• Belau A, Pfisterer J, Wimberger P, Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol 2007;2(18s): abstract 5556
   Google Scholar
• Fresenius Biotech receives approval for Removab by European Commission – First drug worldwide for treatment of malignant ascites. Fresenius Biotech Press Release. 23 April 2009. Available from: http://www.fresenius.de/internet/fag/com/faginpub.nsf/Content/ P-Info+2009+04+23 [Last accessed 28 June 2010]
   Google Scholar
• Lindhofer H, Mocikat R, Steipe B, Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155:219-25
   PubMed Web of Science ®Google Scholar
• Litvinov SV, Velders MP, Bakker HA, Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46
   PubMed Web of Science ®Google Scholar
• Went PT, Meier S, Lugli A, Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004;35:122-8
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mayer A, Gires O, TNF-alpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 2001;21:3499-504
   PubMed Web of Science ®Google Scholar
• Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993;9:516-21
   PubMed Web of Science ®Google Scholar
• De Angelis M, Buley ID, Heryet A, Gray W. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 1992;3:111-17
   PubMed Web of Science ®Google Scholar
• Passebosc-Faure K, Li G, Lambert C, Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res 2005;11:6862-7
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128-35
   PubMed Web of Science ®Google Scholar
• Okamoto S, Ito K, Sasano H, Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med 2005;206:31-40
   PubMed Web of Science ®Google Scholar
• Sebastian M, Passlick B, Friccius-Quecke H, Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunol Immunother 2007;56:1637-44
   PubMed Web of Science ®Google Scholar
• Heiss MM, Stroehlein MA, Jaeger M, Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-43
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Heiss MM, Gamperl H, Safety of catumaxomab: cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites. J Clin Oncol 2009;27(15s): abstract 3036
   Google Scholar
• Chang YS, di Tomaso E, McDonald DM, Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000;97:14608-13
   PubMed Web of Science ®Google Scholar
• Hashizume H, Baluk P, Morikawa S, Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80
   PubMed Web of Science ®Google Scholar
• Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814-19
   PubMed Web of Science ®Google Scholar
• Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med 2004;8:445-54
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38(2S):44-8
   Web of Science ®Google Scholar
• Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005;12:254-61
   PubMedGoogle Scholar
• Walz A, Andratschke M, Wollenberg B, Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. Anticancer Res 2005;25(6B):4239-43
   PubMed Web of Science ®Google Scholar
• Pietzner K, Linke RG, Jager M, Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). J Clin Oncol 2010;28(7s): abstract TPS155
   Google Scholar
• Dettmar K, Atz J, Lindemann C, Establishment of preclinical models to identify clinically useful combinations of trifunctional antibodies with chemotherapy. AACR 2010, abstract 3481
   Google Scholar
• Chekerov R, Reinthaller A, Reimer D, Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian-cancer: results from a phase II study. J Clin Oncol 2010;28(7s): abstract 5039
   Google Scholar
• Holloway R, Roche M, DeMars L, Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: a phase II study. J Clin Oncol 2010;28(7s): abstract 5015
   Google Scholar
• Stroehlein MA, Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis. J Clin Oncol 2006;24(18S): abstract 2544
   Google Scholar
• Heiss MM, Berdov BA, Roman LD, Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: a phase II study. Ann Oncol 2008;19(6S): PD-002
   Google Scholar
• Stroehlein M, Schemanski O, Jaeger M, Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with advanced gastric-, colon- and pancreatic cancer: a pilot phase I study. Proc Gastrointest Cancer Symp 2008: abstract 120
   Google Scholar
• Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 2009;29:3353-9
   PubMed Web of Science ®Google Scholar